Read the Semaglutide Research Guide. Review the research context and evidence limitations.
Semaglutide (60 mg, 30 mg or 10 mg Vial) is supplied for controlled laboratory evaluation of Semaglutide within Weight Loss / Metabolic Research studies.
- Research material: Semaglutide
- Listed strength and format: 60 mg, 30 mg or 10 mg Vial
- Research category: Weight Loss / Metabolic Research
Semaglutide and GLP-1 receptor research
Semaglutide is a GLP-1 analogue described in the 2015 discovery paper by Lau and colleagues. For compound comparisons, Tirzepatide is studied at GIP and GLP-1 receptors, while RTZ-GLP3 / retatrutide is associated with GIP, GLP-1 and glucagon receptor research. These are distinct compounds, not interchangeable vial strengths.
Comparing Semaglutide vial amounts
The 10 mg, 30 mg and 60 mg options are total amounts per vial. Use the selector for the chosen option’s price and availability. An amount in milligrams does not state a prepared concentration or recommend an administration amount. Contact SRP about Semaglutide product details. Published research is background information and does not certify a particular SRP batch.
For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.
















Reviews
There are no reviews yet.